Cutting-edge bio-manufacturing facility to expand regenerative medicine footprint

A pioneering regenerative medicine company based in Australia is making headlines with the official launch of its bio-manufacturing facility. The facility, located at Orthocell’s headquarters in the Murdoch Health and Knowledge Precinct in Western Australia, aims to revolutionise the production and global distribution of their bone regeneration product, Striate+. This milestone achievement not only marks a significant advancement for the biotechnology and manufacturing industries in Australia but also solidifies Perth’s growing reputation as a leader in bio-manufacturing.

With an impressive increase in manufacturing capacity from 10,000 to over 100,000 units per year, thanks to a $23.1 million global exclusive marketing and distribution deal secured with BioHorizons in June 2022, Orthocell is set to reshape the medtech supply chain worldwide.

Orthocell’s Managing Director, Paul Anderson, considers this development a remarkable triumph for Western Australia. He attributed the success to the company’s unwavering dedication to scientific excellence, backed by an extensive program of pre-clinical and clinical studies, as well as regulatory approval in Australia, the European Union, and the United States, with plans to expand into other international markets.

To commemorate this significant occasion, Orthocell’s team was joined by the Honourable Stephen Dawson MLC, Minister for Emergency Services; Innovation and the Digital Economy; Medical Research; and Volunteering. In addition to esteemed clinical and commercial contributors, selected patients who have experienced first-hand the benefits of Orthocell’s regenerative medicine therapies were also in attendance.

The event included an immersive tour of the entire Orthocell headquarters, initially supported by a government grant of $250,000. Over time, the facility has grown into a dynamic hub for Orthocell’s innovative biological products, which have proven to optimise the repair of bone, nerve, tendon, and cartilage injuries. With a team of 36 experts working in-house, alongside esteemed academic collaborators and key opinion leaders, Orthocell continues to push the boundaries of regenerative medicine.

Remplir, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. These products are developed and manufactured on-site at the Orthocell headquarters.

Minister Dawson commended Orthocell for its dedicated efforts in transforming valuable intellectual property into highly attractive global commercial deals, which not only contribute to Western Australia’s resources and employment opportunities but also demonstrate the government’s long-term support for the local manufacturing and biotechnology industries.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.